137 related articles for article (PubMed ID: 2301374)
1. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
van den Anker-Lugtenburg PJ; Sizoo W
Am J Hematol; 1990 Feb; 33(2):152. PubMed ID: 2301374
[No Abstract] [Full Text] [Related]
2. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
3. Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
Randi ML; Fabris F; Girolami A
Haematologica; 1999 Nov; 84(11):1049-50. PubMed ID: 10553169
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
Finazzi G; Barbui T
Pathol Biol (Paris); 2001 Mar; 49(2):167-9. PubMed ID: 11317964
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with melphalan.
Gris JC; Schved JF; Arnaud A; Chauvet C
Am J Hematol; 1989 Jan; 30(1):47-8. PubMed ID: 2910081
[No Abstract] [Full Text] [Related]
6. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
Finazzi G; Ruggeri M; Rodeghiero F; Barbui T
Br J Haematol; 2000 Sep; 110(3):577-83. PubMed ID: 10997967
[TBL] [Abstract][Full Text] [Related]
7. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Randi ML; Fabris F; Girolami A
Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
[TBL] [Abstract][Full Text] [Related]
8. Is hydroxyurea leukemogenic in essential thrombocythemia?
Tefferi A
Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740
[No Abstract] [Full Text] [Related]
9. Evolving management of essential thrombocythaemia.
Barbui T
Eur J Haematol Suppl; 2007 Oct; (68):22-3. PubMed ID: 17727561
[No Abstract] [Full Text] [Related]
10. Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.
Quintás-Cardama A; Pérez-Encinas M; Gonzalez S; Bendaña A; Bello JL
Ann Hematol; 1999 Apr; 78(4):187-8. PubMed ID: 10348150
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
Furgerson JL; Vukelja SJ; Baker WJ; O'Rourke TJ
Am J Hematol; 1996 Feb; 51(2):137-40. PubMed ID: 8579054
[TBL] [Abstract][Full Text] [Related]
12. Acute biphenotypic leukemia arising in a patient with essential thrombocythemia.
Wong GC; Lee LH
Am J Hematol; 2006 Aug; 81(8):624-6. PubMed ID: 16823822
[TBL] [Abstract][Full Text] [Related]
13. Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
Sironi M; Bertola G; Lodato A; Spinelli M; Sciariada L
Acta Haematol; 2003; 109(3):161-2. PubMed ID: 12714827
[No Abstract] [Full Text] [Related]
14. Primary thrombocythemia: new drugs for an evolving disease.
Balduini CL
Haematologica; 1992; 77(4):297-301. PubMed ID: 1427439
[No Abstract] [Full Text] [Related]
15. [Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer].
Horikoshi M; Machida U; Itikawa M; Seo S; Masuda S; Kurokawa M; Ogawa S; Sunaga S; Honda H; Aoki K; Chiba S; Mitani K; Hirai H; Yazaki Y
Rinsho Ketsueki; 2000 Jan; 41(1):68-71. PubMed ID: 10695403
[TBL] [Abstract][Full Text] [Related]
16. When and how to treat essential thrombocythemia.
Barbui T; Finazzi G
N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
[No Abstract] [Full Text] [Related]
17. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
18. [Essential thrombocythemia: conventional therapy].
Grossi A; Vannucchi AM; Longo G; Rafanelli D; Rossi Ferrini P
Haematologica; 1991 Jun; 76 Suppl 3():368-70. PubMed ID: 1752534
[No Abstract] [Full Text] [Related]
19. Implications of the consensus definition of clinical resistance and intolerance to hydroxyurea for clinical practice.
Reilly JT
Eur J Haematol Suppl; 2007 Oct; (68):32-4. PubMed ID: 17727564
[No Abstract] [Full Text] [Related]
20. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
